Xenon Pharmaceuticals Inc. (XENE) News
Follow Xenon Pharmaceuticals Inc. (XENE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Xenon Pharmaceuticals Posts Smaller-Than-Expected Q3 Net Loss
EQUITY | Nov 09, 2026, 09:12 PM UTC
M
Xenon Reports Q3 2026 Financial Results
EQUITY | Nov 09, 2026, 09:01 PM UTC
L
Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:31 PM UTC
M
Xenon Sets November 9 Date for Q3 2026 Results
Xenon said it will report its Q3 2026 financial results on November 9, 2026.
EQUITY | Nov 02, 2026, 09:01 PM UTC
M
Xenon Reports Positive Phase 1 Results for XEN1701 and XEN1120
EQUITY | Oct 29, 2026, 12:37 PM UTC
H
Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call
Xenon Pharmaceuticals (NASDAQ: XENE ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you APIs.
LIVE | Oct 12, 2026, 12:30 PM UTC
M
Xenon Pharma CEO Buys $1.12M in Shares, Stock Rallies
Xenon Pharmaceuticals CEO Ian Mortimer bought 30,000 shares for $1.12 million, part of a larger insider buying spree totaling $1.68 million. The company is advancing its lead epilepsy drug, Azetukalner.
EQUITY | Oct 01, 2026, 04:11 PM UTC
L
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(. - September 29, 2026) - Defence Therapeutics Inc. CSE:DTC (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncolog
NEWS | Sep 29, 2026, 07:18 AM UTC
L
XENE - Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
XENE - Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
NEWS | Sep 21, 2026, 08:01 PM UTC
M
Xenon shares plunge after lead drug trial setback
Xenon said it submitted late Thursday, but the lead drug trial outcome is described as a clinical setback and the stock is reported to be having its worst day since 2017.
EQUITY | Sep 18, 2026, 08:29 PM UTC
H
Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why
Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) shares fell 25.39% to $42.79 in after-hours trading Thursday after the company announced a temporary pause in enrollment for new patients in its ongoing psychiatry studies. Xeno
LIVE | Sep 18, 2026, 06:04 AM UTC
H
Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04, the S&P 500 advancing 1.14% to 7,637.76 and the Nasdaq climbing 1.69% to 26,418.29. These are the top stocks
LIVE | Sep 18, 2026, 01:19 AM UTC
L
XENE: Azetukalner advances toward U.S. approval with robust data, premium pricing, and broad launch plans
Azetukalner is nearing NDA filing for focal onset seizures, with strong efficacy across four doses and plans for premium pricing. Launch will focus on epileptologists, expanding to general neurologists, and leverage a sp
EQUITY | Sep 09, 2026, 07:01 PM UTC
L
XENE’s Azetukalner nears U.S. launch for focal onset seizures
Azetukalner is advancing toward U.S. commercialization for focal onset seizures, with robust efficacy across four doses. Launch is set to target epileptologists and expand to general neurologists under a specialty pharma
EQUITY | Sep 09, 2026, 05:51 PM UTC
L
Xenon Pharmaceuticals to present at Wells Fargo Healthcare conference
Xenon Pharmaceuticals (NASDAQ: XENE) announced it will present at the Wells Fargo Healthcare Conference.
EQUITY | Sep 03, 2026, 08:09 PM UTC
L
XENE - Xenon to Present at Wells Fargo Healthcare Conference
XENE - Xenon to Present at Wells Fargo Healthcare Conference
EQUITY | Sep 03, 2026, 08:01 PM UTC
L
Xenon Pharmaceuticals reports inducement grants under Nasdaq Rule 5635(c)(4)
Xenon Pharmaceuticals reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Aug 28, 2026, 08:07 PM UTC
L
XENE - Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
XENE - Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
EQUITY | Aug 26, 2026, 08:07 PM UTC
L
Xenon Pharmaceuticals Reports Inducement Grants
Xenon Pharmaceuticals grants inducement awards
FX | Jul 31, 2026, 08:01 PM UTC
L
XENE - Xenon to Report Q2 2026 Financial Results on August 6, 2026
XENE - Xenon to Report Q2 2026 Financial Results on August 6, 2026
EARNINGS | Jul 30, 2026, 08:01 PM UTC